

Products Catalog Tyrosine Kinase Inhibitors

Alsachim offers a full set of stable labeled and unlabeled Tyrosine Kinase Inhibitors.

Tyrosine Kinases are a class of enzymes that promotes phosphorylation, which can affect normal cellular functions such as apoptosis, proliferation and differentiation. A kinase dysregulation can cause cancer growth. As Oncology drugs, Tyrosine Kinase Inhibitors were created out of modern genetics and thus represent a change from general to molecular methods of cancer treatment.

Alsachim supports new research developments through a continuous release of new standards.

Product Name	Product N°
Acalabrutinib	C6860
Afatinib	C3767
Alectinib	C6218
Avapritinib	C9269
Axitinib	C2694
Baricitinib	C5984
Bosutinib	C2704
Brigatinib	C7511
Cabozantinib	C3964
Capmatinib	C6188
Ceritinib	C5133
Cobimetinib	C4823
Crizotinib	C2913
Dabrafenib	C3821
Dacomitinib	C6058
Dasatinib	C1773
Decitabine	C3396
Encorafenib	C4277
Entrectinib	C8610
Erdafitinib	C8722
Erlotinib	C1042
Everolimus	C1092
Fedratinib	C5698
Fostamatinib	C8238
Gefitinib	C1964
Gilteritinib	C8215

Product Name	Product N°
[² H ₄]-Acalabrutinib	C6861
[² H ₆]-Afatinib	C4476
[² H ₈]-Alectinib	C6219
[¹³ C, ² H ₃]-Avapritinib	C9270
[¹³ C, ² H ₃]-Axitinib	C2368
[² H ₅]-Baricitinib	C6671
[² H ₉]-Bosutinib	C3709
[¹³ C ₆]-Brigatinib	C7512
[² H ₄]-Cabozantinib	C3965
[¹³ C, ² H ₃]-Capmatinib	C6189
[² H ₇]-Ceritinib	C5748
[¹³ C ₆]-Cobimetinib	C4824
[¹³ C ₂ , ² H ₅]-Crizotinib	C3486
[² H ₉]-Dabrafenib	C3819
[² H ₁₀]-Dacomitinib dihydrochloride	C6059
[² H ₈]-Dasatinib	C923
[¹³ C ₂ , ¹⁵ N ₄]-Decitabine	C3373
[¹³ C, ² H ₃]-Encorafenib	C4198
[¹³ C, ² H ₃]-Entrectinib	C8611
[² H ₆]-Erdafitinib	C8723
[¹³ C ₆]-Erlotinib hydrochloride	C1041
[¹³ C ₂ , ² H ₄]-Everolimus	C903
[² H ₉]-Fedratinib	C8612
[¹³ C, ² H ₃]-Fostamatinib	C8241
[¹³ C, ² H ₃]-Gefitinib	C924
[² H ₅]-Gilteritinib	C8216

*All our products are delivered with a detailed Certificate of Analysis

Product Name	Product N°
Ibrutinib	C4544
Imatinib	C2777
Ipatasertib	C7786
Lapatinib ditosylate salt	C2692
Larotrectinib	C8217
Lenvatinib	C6712
Lorlatinib	C8223
Midostaurin	C4723
Neratinib	C4483
Netarsudil	C8724
Nilotinib	C1077
Nintedanib	C5789
Osimertinib	C6578
Palbociclib	C5107
Pazopanib Hydrochloride	C2129
Pemigatinib	C9184
Peridartinib	C8726
Ponatinib	C4225
Pralsetinib	C9173
Regorafenib	C3604
Ribociclib	C4518
Ripretinib	C9271
Ruxolitinib	C3629
Selpercatinib	C9171
Selumetinib	C4492
Sorafenib	C928
Sunitinib	C904
Tofacitinib	C3926
Trametinib	C3822
Tacatinib	C9273
Vandetanib	C2519
Vemurafenib	C3450

Product Name	Product N°
[² H ₅]-Ibrutinib	C4598
[¹³ C, ² H ₃]-Imatinib	C543
[² H ₆]-Ipatasertib	C7787
[¹³ C, ² H ₇]-Lapatinib	C925
[² H ₄]-Larotrectinib sulfate salt	C8218
[² H ₅]-Lenvatinib	C6767
[¹³ C, ² H ₃]-Lorlatinib	C8224
[¹³ C ₆]-Midostaurin	C4669
[² H ₆]-Neratinib	C4484
[¹³ C, ² H ₃]-Netarsudil	C8725
[¹³ C, ² H ₃]-Nilotinib	C926
[¹³ C, ² H ₃]-Nintedanib	C6405
[¹³ C, ² H ₃]-Osimertinib	C6579
[² H ₈]-Palbociclib	C5108
[¹³ C, ² H ₃]-Pazopanib Hydrochloride	C2128
[² H ₈]-Pemigatinib	C9185
[¹³ C, ² H ₄]-Peridartinib	C8727
[² H ₈]-Ponatinib	C4226
[¹³ C ₄]-Pralsetinib	C9174
[¹³ C, ² H ₆]-Regorafenib	C3605
[² H ₆]-Ribociclib	C4503
[¹³ C ₆]-Ripretinib	C9272
[² H ₉]-Ruxolitinib	C3600
[¹³ C, ² H ₃]-Selpercatinib	C9172
[¹³ C ₂ , ² H ₄]-Selumetinib	C4493
[¹³ C, ² H ₃]-Sorafenib	C525
[² H ₁₀]-Sunitinib	C895
[¹³ C ₃ , ¹⁵ N]-Tofacitinib	C3928
[¹³ C ₆]-Trametinib	C3820
[¹³ C ₆]-Tacatinib	C9274
[¹³ C ₆]-Vandetanib	C2520
[¹³ C ₆]-Vemurafenib	C3451



www.alsachim.com

Check our online catalog and create your free account.



A specific need?

contact us and benefit from custom synthesis service to meet your specific requirements

ALSACHIM

a Shimadzu Group Company

160 rue Tobias Stimmer
67400 Illkirch Graffenstaden - France
Tel.: +33 (0)390 - 402 200
Fax.: +33 (0)390 - 402 199
contact@alsachim.com
www.alsachim.com

For Research Use Only. Not for use in diagnostic procedures.

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Alsachim.

© Alsachim, 2020